Advanced Hepatocellular Carcinoma
Conditions
Interventions
Experimental group:Lenalidomide combined with targeted therapy and immunotherapy
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years and = 1.0×10^9/L, platelets >= 60×10^9/L, Hb >= 80 g/L, CrCl >= 30 mL/min, ALT/AST <= 5×ULN, total bilirubin <= 3 mg/dL; 9. The viral status of HBV, HCV, etc. has been evaluated; HBsAg positive or those with previous HBV infection must undergo liver disease specialist assessment and receive antiviral prophylaxis as needed.
Exclusion criteria
Exclusion criteria: 1.Primary resistance to the most recent targeted therapy plus ICI regimen, defined as unequivocal disease progression within 6 weeks or 2 treatment cycles without any evidence of prior clinical benefit; 2.Prior exposure to lenalidomide or a history of severe hypersensitivity to lenalidomide or thalidomide; 3.Explosive disease progression, or situations in which continuation of the existing treatment backbone is deemed clinically unreasonable by the investigator; 4.Uncontrolled ascites, hepatic encephalopathy, or active gastrointestinal bleeding; active severe infections, including uncontrolled HBV replication, tuberculosis, severe pulmonary infection, or other serious infections; 5.Persistent treatment-related toxicities of grade >=2 that have not recovered to baseline or acceptable levels at study entry; 6.Creatinine clearance (CrCl) <30 mL/min; 7.Pregnancy, breastfeeding, or inability/unwillingness to comply with contraceptive requirements;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6-month PFS rate;Incidence of grade >=3 treatment-related adverse events (TRAEs); | — |
Countries
China
Contacts
Public ContactShunda Du
Peking Union Medical College Hospital
Outcome results
None listed